These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12890849)

  • 1. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
    Drüeke TB; McCarron DA
    N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
    [No Abstract]   [Full Text] [Related]  

  • 2. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Kida Y
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14626256
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Colussi G
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14614175
    [No Abstract]   [Full Text] [Related]  

  • 8. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
    Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
    Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
    Moe SM; Zekonis M; Harezlak J; Ambrosius WT; Gassensmith CM; Murphy CL; Russell RR; Batiuk TD
    Am J Kidney Dis; 2001 Oct; 38(4):792-802. PubMed ID: 11576883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC; Mawad H; Malluche HH
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival differences between activated injectable vitamin D2 and D3 analogs.
    Kalantar-Zadeh K
    Kidney Int; 2007 Apr; 71(8):827; author reply 827-8. PubMed ID: 17429422
    [No Abstract]   [Full Text] [Related]  

  • 15. Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
    Teng M; Wolf M; Ofsthun MN; Lazarus JM; Hernán MA; Camargo CA; Thadhani R
    J Am Soc Nephrol; 2005 Apr; 16(4):1115-25. PubMed ID: 15728786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of calcitriol on renal anemia in patients under chronic hemodialysis].
    Abou-Khalil N; Makó J
    Orv Hetil; 1996 Jul; 137(27):1469-72. PubMed ID: 9173368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Ratnam S; Kaw D; Rao P
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14626257
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
    Lund RJ; Andress DL; Amdahl M; Williams LA; Heaney RP
    Am J Nephrol; 2010; 31(2):165-70. PubMed ID: 20016142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
    Seeherunvong W; Nwobi O; Abitbol CL; Chandar J; Strauss J; Zilleruelo G
    Pediatr Nephrol; 2006 Oct; 21(10):1434-9. PubMed ID: 16900383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.